OPIANT PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
OPIANT PHARMACEUTICALS INC. - More news...
OPIANT PHARMACEUTICALS INC. - More news...
- Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
- Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
- Indivior PLC to Acquire Opiant Pharmaceuticals
- Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
- Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
- Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
- Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
- Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene
- Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose
- Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
- Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
